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Introduction
Invasive tracheobronchial infection with Aspergillus 
is an extremely serious clinical condition with its 
pseudomembranous tracheobronchitis (PTB) variant being 
the most lethal even after appropriate and timely treatment 
with antifungals. Central airway obstruction due to adherent 
and extremely hard to remove pseudomembranes adds to the 
clinical complexities. We describe a challenging case of PTB 
where step-wise multimodality complex airway treatment 
played a vital role in achieving desired clinical outcome.
Case presentation 
A 69-year-old woman with diffuse large B-cell lymphoma 
and Sjogren’s syndrome was hospitalized for recurrent 
pneumonias in the setting of neutropenia two months after 
completing chemotherapy. She had received six cycles of 
dose adjusted EPOCH (Etoposide, Prednisone, Vincristine, 
Cyclophosphamide, Doxorubicin) with Rituximab. The 
patient was also on hydrocortisone 10 mg in morning and 
5 mg in evening for adrenal insufficiency diagnosed 6 weeks 
prior to presentation. CT chest showed consolidation in 
bilateral lower lobes and a soft tissue density in the right 
main stem bronchus with significant narrowing (Figure 1). 
She didn’t improve with multiple courses of antibiotics 
including appropriate coverage for Pseudomonas aeruginosa 
found in sputum and therefore a flexible bronchoscopy 
was requested. The patient had also developed significant 
dyspnea by this time and hypoxemia requiring 4 liters of 
supplemental oxygen. Flexible bronchoscopy revealed 
yellowish thick adherent membranes in the right main stem 
with 75% occlusion extending up to bronchus intermedius 
(Figure 2A). The areas below the level of obstruction were 
severely inflamed with purulent thick secretions. Attempts 
to debulk the lesion with Argon Plasma Coagulation (APC) 
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and biopsy forceps met with limited success. The patient 
was thus intubated with a 10 mm outer diameter (OD) 
Bryan-DumonTM rigid bronchoscope (small OD scope was 
used as her overall airway size was small) and the stenotic 
area was dilated with Controlled radial expansion (CRETM) 
pulmonary balloon dilator (Boston Scientific, Natick, MA) 
size 8-9-10 mm up to 9 mm (Figure 2B). Debulking with 
biopsy forceps (Figure 2C) and balloon dilatation restored 
patency to the right main stem (Figure 2D). Biopsies of these 
abnormal areas showed significant acute inflammation and 
necrosis with fungal organisms consistent with Aspergillus. 
A diagnosis of Aspergillus  PTB with central airway 
obstruction was made and the patient was started on 
oral Voriconazole 250 milligram twice a day along with 
intravenous immune globulin for hypogammaglobulinemia.
A repeat flexible bronchoscopy was performed 4 weeks 
later to reassess the impact of therapy. This revealed 
significant worsening of the central airway stenosis with 
diffuse yellow thick adherent lesion almost completely 
obstructing the right main stem bronchus. This was 
extremely challenging as both the therapeutic flexible and 
even the pediatric bronchoscopes couldn’t be advanced 
through this area of narrowing. Additionally biopsy forceps 
was not helpful in achieving any degree of debulking. 
Therefore patient was intubated with 10 mm OD Bryan-
DumonTM rigid bronchoscope and some debulking was 
performed using a combination of APC, biopsy forceps and 
rigid bronchoscope. The stenotic area was initially dilated 
with a 5 French Fogarty catheter. Then sequential dilatation 
of right main stem was performed with 8 mm OD rigid 
bronchoscopes along with a size 8-9-10 CRE pulmonary 
Figure 1 Axial CT chest prior to the bronchoscopic interventions, 
black arrow showing severe obstruction of the right main stem.
Figure 2 Sequential images of flexible and rigid bronchoscopy. (A) Aspergillus pseudomembranous tracheobronchitis of the distal trachea 
and causing severe obstruction of the right main stem (white arrow); (B) balloon dilation of right main stem; (C) mechanical debulking of the 
right main stem obstructive lesion; (D) patent right main stem at the end of the initial bronchoscopic intervention; (E) Severely obstructed 
right upper lobe; (F) stenting of the right main stem using the covered metallic stent; (G) the right secondary carina silicone Y stent in place; 
(H) patent right upper lobe opening due to right secondary carina silicone Y stent.
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balloon catheter. Only the proximal right main stem was 
dilated with the 8 mm OD rigid bronchoscope with inability 
to advance further distally to the distal right main stem and 
bronchus intermedius. The right upper lobe opening was 
also 90% occluded (Figure 2E) and was dilated with 5 French 
Fogarty catheter. Placement of a peripheral 10-7-7 mm Y 
silicone stent customized for the right upper lobe opening 
was attempted several times to maintain patency of right 
upper lobe along with right main stem with no success due 
to significant generalized inflammation causing narrowed 
and abnormal angled right upper lobe opening. Finally, the 
patient was intubated with a rigid bronchoscope 10 mm OD 
and an 8 mm × 15 mm covered metallic (hybrid) AERO stent 
(Alveolus, Inc., NC, USA) was placed in the right main stem 
(Figure 2F) to maintain patency of the right main stem and 
to achieve potential dilatation over time due to the radial 
expansive force of the stent. In addition to increasing the 
dose of oral Voriconazole to 300 mg twice a day, the patient 
was also started on 25 mg of aerosolized Amphotericin B 
once a day. The patient remained on her usual regimen of 
antihypertensive medications, proton pump inhibitors and 
maintenance hydrocortisone.
Flexible bronchoscopy was repeated 2 weeks later. The 
patient had again developed worsening of dyspnea. The 
right main stem patency was maintained by the stent but the 
right upper lobe bronchus had almost completely occluded 
with a barely <4 mm opening. The patient was intubated 
with 10 mm OD rigid bronchoscope and the AERO stent 
was removed. The right main stem bronchus maintained 
better luminal patency as compared to that observed during 
the previous bronchoscopy likely due to the AERO stent. 
The right upper lobe opening was sequentially dilated to 
8 mm using a 2 mm × 6 mm biliary balloon, a 7 French 
Fogarty catheter, and a 2 mm × 8 mm biliary balloon 
respectively. The right main stem and bronchus intermedius 
were dilated to 10 mm using an 8-9-10 mm CRETM balloon. 
A customized 10-7-7 mm Y silicone stent (Lengths: right main 
stem—15 mm, bronchus intermedius—5 mm and right upper 
lobe—5 mm) without studs (Hood Laboratories, Pembroke, 
MA) was then successfully deployed as the right main stem 
was more patent and allowed us to overcome the technical 
difficulties that we encountered earlier (Figure 2G,H). 
The patients’ symptoms improved significantly after 
placement of the peripheral Y stent. Follow up CT showed 
patent airways (Figure 3) and surveillance bronchoscopies 
performed at monthly intervals twice did not show 
any evidence of recurrent central airway stenosis. The 
peripheral Y stent was removed after one year without any 
evidence of abnormal infected mucosa underneath and the 
pseudomembranes had completely resolved. The right-sided 
involved airway had developed fibrosis and some stenosis 
but still maintained its patency at approximately 70% of the 
original size (Figure 4) and this was also noted on subsequent 
CT of the chest (Figure 3). The patient completed one year 
of oral Voriconazole therapy and remained asymptomatic 
with good performance status without any further clinical 
deterioration or recurrence of infection. 
Discussion
Aspergillus is a ubiquitous fungus and the aerosolized 
spores frequently get inhaled and get deposited in the 
human airways. In healthy people, innate immunological 
and mucociliary defenses effectively eliminate the spores. 
However invasive aspergillosis can be seen in people 
with defective immunity like those with neutropenia, 
hematological malignancies, organ transplant, diabetes 
mellitus, long-term corticosteroid use etc. Similarly this 
condition can also be encountered in those with structural 
lung disease and defective mucociliary mechanism like those 
with chronic obstructive lung disease and sarcoidosis (1). 
A small fraction of patient (approximately 10%) with 
invasive aspergillosis may be immunocompetent. Aspergillus 
can cause invasive tracheobronchial disease, which 
ultimately requires a bronchoscopy for diagnosis and 
tracheobronchial invasive involvement is subcategorized into 
ulcerative, obstructive and pseudomembranous variants (1). 
Pseudomembrane tracheobronchitis (PTB) is caused by 
invasion of tracheobronchial mucosa by aspergillus with 
necrosis and sloughing off of tissue into airway and is the 
variant with the most aggressive clinical course and a high 
Figure 3 Axial CT chest showing patent right main stem after 
removal of the secondary carina Y silicone stent.
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fatality rate in spite of treatment and irrespective of immune 
status of the patient (2-4). Currently there is no system 
of classification of severity of PTB but literature suggests 
that the subgroup the patients who require mechanical 
ventilation have the lowest chance of survival (3,4). As the 
obstructing pseudomembranes may be responsible for 
poor antifungal penetration and also for development of 
respiratory failure, therefore maintaining the patency of the 
central airway to prevent progressive respiratory failure and 
allowing more time for the antifungal medications to work 
may be an extremely critical factor in such patients.
Our case demonstrates several complexities of management 
of central airway obstruction of the patients with PTB. 
First of all, our patients had genetically smaller airways 
making them more prone to be completely obstructed 
with tissue debris and we had to use relatively smaller rigid 
bronchoscope and smaller balloons to dilate the airway 
including the use of Fogarty catheters and biliary balloons. 
Understanding the utility of accessories available with our 
gastroenterology colleagues was helpful. Secondly the 
difficulty in removal of extensive thick and sticky obstructive 
debris is well described. Even thermal techniques like 
APC, electrocautery, laser and cryotherapy may not work 
well as seen in this case although combination with rigid 
bronchoscopic debulking was helpful. Thirdly, extreme 
caution needs to be exercised when removing these 
membranes as patient death has been reported from massive 
pulmonary artery bleed during removal of obstructive 
infective tissue (5). Careful review of CT imaging may 
be of some help to know the relationship of involved 
airway with major blood vessels and to assess the risk of 
major bleeding. Additional imaging modalities like CT 
pulmonary angiography, digital subtraction angiography 
and endobronchial ultrasound or interventions like 
embolization prior to bronchoscopic procedures in high 
risk cases may be helpful but have not been well described 
in literature. We cautiously removed some debris to obtain 
the patency of right main stem and placed an AERO hybrid 
stent to slowly dilate the right main stem over several days, 
as we were not able to initially place a peripheral Y stent, 
which could have allowed us to maintain the patency of 
right upper lobe. Fourthly, there is limited literature on 
the appropriate selection of airway stents for PTB. The 
deployment of metallic or hybrid airway stent has been 
reported in post-transplant tracheobronchial stump stenosis 
due to aspergillus infection (2,6). The use of silicone stents 
has been described only on rare occasions in the setting of 
Aspergillus tracheobronchial infection including one case 
for airway stenosis after treatment of bronchomediastinal 
fistula and another for post-tuberculosis tracheal stricture 
with superimposed PTB (7,8). Finally, the issue of placing 
an airway stent in the setting of infection is a subject of 
debate (8). Pornsuriyasak et al. described a case of PTB 
superimposed on post-tubercular tracheal stricture. They 
dilated the trachea with rigid bronchoscope and avoided 
placing a stent in the setting of acute infection. The patient 
showed clinical improvement flexible bronchoscopy a week 
later showed improved pseudomembranes. The patient 
developed recurrent tracheal stricture in the absence 
of PTB and a silicone stent was placed. In our case, the 
patient likely had more severe and more extensive PTB 
and there was clinical deterioration in spite of appropriate 
antifungal therapy and there was no choice but to place a 
stent to prevent further worsening of respiratory status. 
Figure 4 Bronchoscopy after removal of right secondary carina silicone Y stent. (A) Right main stem patent with some residual narrowing 
and fibrosis; (B) right upper lobe opening is patent with some granulation tissue related to the stent.
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The obstructive exudates still progressed and obstructed the 
right upper lobe with clinical deterioration but the hybrid 
stent kept the right main stem bronchus patent. This also 
possibly allowed us to achieve some slow right main stem 
dilatation and finally placement of a peripheral silicone Y 
stent. Finally, to the best of our knowledge, a peripheral Y 
stent has never been placed in the setting of PTB and was 
an additional unique and challenging aspect of this case. 
The techniques of peripheral Y stents have been described 
previously (9,10) but usual anatomical factors can pose 
significant challenges in deployment (11). We were able to 
successfully deploy a peripheral Y stent even in the setting 
of diffuse airway obstruction by PTB. This was not only 
associated with immediate clinical improvement but also 
allowed the antifungal therapy to take effect thus allowing 
our patient a better chance at survival.
In summary, we describe the challenges faced in the 
complex multimodality management of central airway 
obstruction of a patient with PTB. We believe that 
thoughtful, cautious and determined airway management 
may help in slowing the clinical deterioration of this 
aggressive airway infection, which may offer a chance of 
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